Taliaz News
11 articlesCerba and Taliaz to Leverage Artificial Intelligence and Genetics Expertise to Improve Patient Care Management in Depression
growth-positive
Taliaz Announces CE Certification for Its PREDICTIX Digital AI Mental Health Solution
Taliaz, a mental health startup, has completed CE Certification for its product PREDICTIX Digital. The digital decision-support and management solution will provide European health care and telehealth providers with instant digital prescribing recommendations for mental health treatment. This will help optimize treatment and management while lowering costs. The burden on health systems to diagnose and treat mental health disorders has increased during the COVID-19 pandemic. PREDICTIX Digital uses AI to analyze patient data and provide personalized recommendations for antidepressants. The CE certification is an important milestone for Taliaz as it expands its PREDICTIX technology into Europe and other new markets. Taliaz is also raising additional investment to further accelerate and expand its commercial efforts.
CustomersPartnersInvestment
growth-positive
Israeli mental health startup awarded $2.7 million EU grant for AI solution
Israeli health startup Taliaz Health Ltd. has been awarded a $2.7 million grant from the European Unions Horizon 2020 program. The grant aims to support further clinical research and development of Taliazs mental health platform, PREDICTIX. The platform uses AI to examine patient records and provide suggestions for treatment. Taliaz plans to expand its clinical research to Europe and improve mental health, specifically focusing on patient depression. The company is also raising additional investments to expand its efforts and collaborate with healthcare systems and providers worldwide.
InvestmentExpand
Hillel's Tech Corner: Minimizing the mental health mystery
Israeli startup uses AI to find best depression treatment
Global mental health: raising awareness and fighting stigma
growth-positive
Artificial intel finds best antidepressant for a patient
Taliaz, a Tel Aviv-based health-analytics company, has partnered with Psychiatry UK to launch an online service called Predictix. The service uses artificial intelligence-driven genetic testing to help psychiatrists identify the right antidepressant medication for depression sufferers. By analyzing patients unique biological background and environment, the Predictix AI algorithm personalizes treatment. The service is fully online, non-invasive, and easy to use from home. Patients consult with psychiatrists and send a DNA swab for analysis. The psychiatrists receive scientific guidance within days, based on the patients genetic makeup and health record. The service was launched in February after a successful pilot phase. Taliaz also offers Predictix in France and Israel.
CustomersPartners
growth-positive
Can AI Help Doctors Treat Depression? These Startups Think So
Taliaz, an AI-driven startup, has developed a decision support tool called PREDICTIX to help doctors identify the right antidepressant medication for patients. The tool uses deep scientific research, genetics, neurological, environmental, and clinical data to predict efficacy and adverse effects of current antidepressants. Taliaz has launched an online AI-driven genetic testing service for depression sufferers in partnership with Psychiatry UK LLP. Another Israeli company, Elminda, has received EUR 2.8M from the European Commission to bring its brain analytics product, BNA-PREDICT, to European patients suffering from depression. The product predicts responsiveness to antidepressants and neurostimulation treatments. The article highlights the increasing importance of sound mental health and the potential for AI to improve emotional well-being.
Customers
growth-positive
How Israel Turned Decades Of Medical Data Into Digital Health Gold
The Israel Ministry of Health is leveraging its medical data to create new opportunities in the analysis and optimization of patient treatment. The country has a centralized health system with a linked electronic medical records platform, providing access to patient records across healthcare institutions. Prime Minister Benjamin Netanyahu announced a $300 million initiative in 2018 to make this data available for research and development. The digitization project aims to use big data analysis and AI systems to identify correlations in conditions and treatments, improve early detection of diseases, and develop personalized medical treatments. Israeli companies, such as Maccabi Healthcare and Taliaz, have already developed solutions using big data analysis to identify cancer risks and adjust antidepressant doses for patients. The project also supports the trend towards home hospitalization using advanced sensor technology. Israels small size and advanced technology make it an ideal testing ground for healthcare system challenges worldwide.
CustomersPartners
growth-positive
הסטארטאפ הישראלי הזה יוודא שתקבלו רק את התרופות שמתאימות לכם
Israeli startup Taliaz has developed a platform that uses AI and machine learning to create personalized drug treatments based on individual patient data. The companys solution, PREDICTIX, provides doctors with a predictive report that allows them to tailor treatment plans for each patient. The system is currently being implemented in Israels health system, following a successful bid for a 30 million shekel contract. Taliaz has also begun marketing activities in the UK, in collaboration with genetic laboratories and Psychiatry-UK. The company was founded in 2012 and has raised approximately $1.3 million to date.
CustomersPartnersInvestment
growth-positive
חברת Taliaz פיתחה טכנולוגיה להתאמת תרופות נגד דיכאון
Taliaz has won a tender from the Ministry of Health to implement an algorithm for personalized depression treatment. The technology will be integrated into the mental health system of the Ministry of Health with an initial investment of 2.4 million shekels and a commitment to further investment of 30 million shekels. Taliazs algorithm, based on the Star D research, accurately matches medications to 8 out of 10 patients. The antidepressant drug market is estimated at $15 billion annually. Taliaz is also partnering with Maccabi Healthcare Services and Dr. Ilan Tal, a private psychiatrist, for further development.
Customers
